Your new experience awaits. Try the new design now and help us make it even better

REVIEW article

Front. Immunol.

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1684549

This article is part of the Research TopicThe Role of Immunotherapy in Cancer Therapy and Its ChallengesView all 5 articles

Biomarkers and Immunotherapy in Endometrial Cancer: Mechanisms and Clinical Applications

Provisionally accepted
Lianfang ZhaoLianfang Zhao1Xiaohong LiXiaohong Li1Liping TangLiping Tang1Yaling JingYaling Jing1Fang LinFang Lin1Yongqiang ZhangYongqiang Zhang2Yuqin TangYuqin Tang3,4Chuanliang ChenChuanliang Chen4Jiayan YangJiayan Yang1Xiaofang LiuXiaofang Liu1*Jianhui ChenJianhui Chen1*
  • 1Department of Medical Genetics, Suining Central Hospital, Suining, China
  • 2Institute of Cancer Research, Henan academy of Innovations in Medical Science, Zhengzhou, China
  • 3Department of Anesthesiology and Perioperative Medicine, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, China
  • 4Clinical Bioinformatics Experimental Center, Henan Provincial People's Hospital, Zhengzhou university, Zhengzhou, China

The final, formatted version of the article will be published soon.

Select one of your emails

You have multiple emails registered with Frontiers:

Notify me on publication

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

Advanced endometrial cancer (EC) poses significant therapeutic challenges due to molecular heterogeneity and immune evasion. Immune checkpoint inhibitors (ICIs) show promise, particularly in mismatch repair-deficient (MMRd) and POLE-mutated subtypes, but resistance remains a barrier. This review synthesizes recent advances in biomarker-driven immunotherapy for EC, focusing on predictive biomarkers (e.g., LRP2, FANCE, MSH2, miRNA signatures), combination strategies (ICIs with anti-angiogenics or PARP inhibitors), and challenges in clinical translation. We highlight the impact of tumor microenvironment components, emerging technologies like machine learning, and future directions for personalized immunotherapy. Standardizing biomarker testing and optimizing trial designs will be critical to overcome resistance and improve outcomes.

Keywords: endometrial cancer, Immunotherapy, biomarkers, immune checkpoint inhibitors, combination therapy

Received: 12 Aug 2025; Accepted: 06 Oct 2025.

Copyright: © 2025 Zhao, Li, Tang, Jing, Lin, Zhang, Tang, Chen, Yang, Liu and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Xiaofang Liu, 250549749@qq.com
Jianhui Chen, chenjianhui0913@163.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Supplementary Material